Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xiaochuan Jiaonang is a traditional Chinese medicine (TCM) oral capsule developed and manufactured by Guizhou Baite Pharmaceutical. It is an approved pharmaceutical product in China indicated for the treatment of asthma and related respiratory symptoms such as coughing and wheezing. The formulation typically consists of a blend of herbal extracts, including Ephedra (Ma Huang), which contains ephedrine and pseudoephedrine. These alkaloids function as non-selective adrenergic receptor agonists, promoting bronchodilation and relieving airway obstruction. Other ingredients such as Bitter Almond and Licorice provide additional antitussive and anti-inflammatory benefits, making it a comprehensive treatment for chronic respiratory conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xiaochuan Jiaonang.